Real-World Outcomes of Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Third-Line Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Single-Center Study

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common diagnosed aggressive B-cell lymphoma, with poor outcomes in those who experience relapsed or refractory (R/R) disease. Landmark clinical trials have demonstrated the efficacy and safety of anti-CD19 chimeric antigen receptor (CAR)...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Aishwarya Sridhar, Thomas S. Gunning, Alexandra Della Pia, Xiaopei Zhang, Jaeil Ahn, Brittany Sinclaire, Brittany Lukasik, Christina Cho, Michele L. Donato, Sukhdeep Kaur, Hyung C. Suh, Lori A. Leslie, Tatyana A. Feldman, Andre H. Goy, Andrew Ip
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2025-01-01
Edice:	Hemato
Témata:	diffuse large B-cell lymphoma DLBCL non-Hodgkin lymphoma NHL cytokine release syndrome CRS
On-line přístup:	https://www.mdpi.com/2673-6357/6/1/3
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!